Prendergast B D, Anning P B, Lewis M J, Shah A M
Department of Cardiology, University of Wales College of Medicine, Cardiff, UK.
Cardiovasc Res. 1997 Jan;33(1):131-8. doi: 10.1016/s0008-6363(96)00174-5.
TO examine the effects of endogenous endothelin-1 on cardiac contraction in the isolated heart using endothelin receptor antagonists.
Isolated ejecting guinea-pig hearts were perfused with Krebs buffer (1 microM indomethacin) at 37 degrees C, constant loading and heart rate, and high-fidelity left ventricular pressure was monitored by an apical 2F Millar catheter. The effects of the following interventions on left ventricular performance and coronary flow were determined: (a) no treatment (i.e., time controls) (n = 8); (b) the specific ETA receptor antagonist, BQ123 (1 microM, n = 8); (c) the specific ETB receptor antagonist, IRL 1038 (0.1 microM, n = 4; 1 microM, n = 6); (d) exogenous endothelin-1 (0.01 nM, n = 6; 0.1 nM, n = 6); (e) the specific ETB receptor agonist, BQ3020 (5 nM, n = 8).
All parameters were stable in control (untreated) hearts. BQ123 induced progressive acceleration of early left ventricular pressure decline and a fall in left ventricular end-diastolic pressure with no effect on peak left ventricular pressure, dP/dtmax, stroke volume or coronary flow. IRL 1038 had no effect on any of these parameters. In contrast, exogenous endothelin-1 exerted potent vasoconstrictor effects associated with a fall in peak left ventricular pressure, dP/dtmax and stroke volume. Similar changes were observed with BQ3020. Concentrations of endothelin-1 < 0.1 nM, which had no vasoconstrictor effect, produced no change in LV function.
These data indicate that basal intracardiac release of endothelin-1 significantly delays LV relaxation in the isolated guinea-pig heart, but has no effect on coronary flow. The contrasting effects of endogenous endothelin-1 (elicited by BQ123) and exogenous endothelin-1 are likely to reflect differences in their site of action and in their effective concentrations at these sites.
使用内皮素受体拮抗剂研究内源性内皮素 -1 对离体心脏心肌收缩的影响。
将离体的豚鼠跳动心脏在 37℃ 下用 Krebs 缓冲液(含 1μM 吲哚美辛)进行灌注,保持负荷和心率恒定,通过心尖 2F 米拉尔导管监测高保真左心室压力。确定以下干预措施对左心室功能和冠状动脉血流的影响:(a) 不进行处理(即时间对照,n = 8);(b) 特异性 ETA 受体拮抗剂 BQ123(1μM,n = 8);(c) 特异性 ETB 受体拮抗剂 IRL 1038(0.1μM,n = 4;1μM,n = 6);(d) 外源性内皮素 -1(0.01 nM,n = 6;0.1 nM,n = 6);(e) 特异性 ETB 受体激动剂 BQ3020(5 nM,n = 8)。
在对照(未处理)心脏中所有参数均稳定。BQ123 导致左心室压力早期下降逐渐加速,左心室舒张末期压力降低,而对左心室峰值压力、dP/dtmax、每搏输出量或冠状动脉血流无影响。IRL 1038 对这些参数中的任何一个均无影响。相比之下,外源性内皮素 -1 产生强烈的血管收缩作用,伴有左心室峰值压力、dP/dtmax 和每搏输出量下降。使用 BQ3020 观察到类似变化。浓度低于 0.1 nM 的内皮素 -1 无血管收缩作用,对左心室功能无影响。
这些数据表明,内源性内皮素 -1 在离体豚鼠心脏中的基础心脏内释放显著延迟左心室舒张,但对冠状动脉血流无影响。内源性内皮素 -1(由 BQ123 引发)和外源性内皮素 -1 的不同作用可能反映了它们作用部位及其在这些部位的有效浓度的差异。